GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thor Medical ASA (FRA:8NN) » Definitions » Long-Term Capital Lease Obligation

Thor Medical ASA (FRA:8NN) Long-Term Capital Lease Obligation : €0.03 Mil (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Thor Medical ASA Long-Term Capital Lease Obligation?

Thor Medical ASA's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.03 Mil.

Thor Medical ASA's quarterly Long-Term Capital Lease Obligation increased from Dec. 2023 (€0.00 Mil) to Jun. 2024 (€0.04 Mil) but then declined from Jun. 2024 (€0.04 Mil) to Dec. 2024 (€0.03 Mil).

Thor Medical ASA's annual Long-Term Capital Lease Obligation stayed the same from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil) but then increased from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€0.03 Mil).


Thor Medical ASA Long-Term Capital Lease Obligation Historical Data

The historical data trend for Thor Medical ASA's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thor Medical ASA Long-Term Capital Lease Obligation Chart

Thor Medical ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 - - - 0.03

Thor Medical ASA Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.04 0.03

Thor Medical ASA  (FRA:8NN) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Thor Medical ASA Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Thor Medical ASA's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Thor Medical ASA Business Description

Industry
Traded in Other Exchanges
Address
Karenslyst Alle 9C, Oslo, NOR, 0278
Thor Medical ASA is a Norway-based biopharmaceutical company. The Company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. The Company has developed a proprietary technology for the manufacturing of radionuclides, alpha-particle emitters from natural resources. The high energy deposition and the short range of alpha particles make it possible to eradicate cancer cells while minimizing damage to nearby healthy cells.

Thor Medical ASA Headlines

No Headlines